Cellectricon Launches World's First System for High Throughput RNAi Screening



    GOTHENBERG, Sweden, March 27 /CNW/ - Cellectricon, a leading provider of
screening solutions for drug discovery, today announced the launch of the new
Cellaxess(R)HT System. The world's first fully automated high throughput
transfection system enables reagent-free delivery of genetic material to a
wide range of biologically relevant cell types. The system will be introduced
at the SBS 14th Annual Conference and Meeting in St. Louis, MO, USA, April 6 -
10.
    Cellectricon has developed Cellaxess(R)HT in close collaboration with
leading research groups to meet the increasing demand for a technology capable
of genome-wide RNAi screening.
    "We are very pleased to meet the industry's demand by bringing this
state-of-the-art system to the market," says Dr. Mattias Karlsson, CEO of
Cellectricon. "Cellaxess(R)HT will revolutionize target discovery by opening
the door to using more biologically relevant cell types in genome-wide RNAi
screening."

    About the Cellaxess(R)HT system

    Cellaxess(R)HT addresses the critical need for high throughput delivery
of siRNA and cDNA to hard to transfect cells in several cell-based screening
assays. Cellaxess(R)HT is the only fully automated system on the market
allowing for high throughput transfection of cells in culture directly in
384-well microplates. The system enables reagent-free delivery to a wide range
of biologically relevant cell types with excellent efficiency and viability at
a throughput of 50 000 wells per day.

    About Cellectricon

    Cellectricon is a key innovator and solutions provider of advanced
cell-based screening products to accelerate biotechnology and drug discovery.
The company's successfully launched products are aimed at critical bottlenecks
in the drug discovery process and have been adopted by top-reference customers
including the top ten pharmaceutical companies. To date, the company has
launched two products with exceptional market acceptance targeting the ion
channel screening and transfection markets. The company utilizes
state-of-the-art interfaces to biological systems by employing novel
microfabrication technologies and smart engineering solutions. This enables
completely new types of assays and devices with superior performance
characteristics and robustness.





For further information:

For further information: Susanne Fagerlund, VP Market Communications,
Phone: +46(0)31-760-35-15, E-mail: susanne.fagerlund@cellectricon.com

Organization Profile

CELLECTRICON AB

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890